Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study
Authors:
Open Access
- 5 August 2023
- journal article
- research article
- Published by Springer Nature in Molecular Cancer
- Vol. 22 (1) , 1-11
Abstract
Background: Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study aimed to examine anlotinib plus icotinib as a first-line treatment option for advanced NSCLC carrying EGFR mutation with or without concurrent mutations. Methods: This phase 2, single-arm, multicenter trial (ClinicalTrials.gov NCT03736837) was performed at five hospitals in China from December 2018 to November 2020. Non-squamous NSCLC cases with EGFR-sensitizing mutations were treated with anlotinib and icotinib. The primary endpoint was progression-free survival (PFS). Secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival (OS), and toxicity. Results: Sixty participants were enrolled, including 31 (52%) and 29 (48%) with concurrent mutations and pathogenic concurrent mutations, respectively. The median follow-up was 26.9 (range, 15.0-38.9) months. ORR and DCR were 68.5% and 98.2%, respectively. Median PFS was 15.1 (95%CI: 12.6–17.6) months which met the primary endpoint, median DoR was 13.5 (95%CI: 10.0-17.1) months, and median OS was 30.0 (95%CI: 25.5–34.5) months. Median PFS and OS in patients with pathogenic concurrent mutations were 15.6 (95%CI: 12.5–18.7) months and not reached (95%CI: 17.46 months to not reached), respectively. All patients experienced TRAEs, including 26 (43%) and 1 (1.7%) who had grade ≥ 3 and serious treatment-related adverse events (TRAEs). Conclusions: Anlotinib combined with icotinib was effective and well-tolerated as a first-line treatment option for EGFR mutation-positive advanced NSCLC with or without concurrent mutations. Trial registration: ClinicalTrials.gov identifier: NCT03736837.Keywords
Funding Information
- National Nature Science Foundation of China (No. 82172635)
- National Natural Science Foundation of China (No. 82203628)
This publication has 45 references indexed in Scilit:
- Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approachesTherapeutic Advances in Respiratory Disease, 2015
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study2015
- Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung CancerClinical Cancer Research, 2014
- MutationTaster2: mutation prediction for the deep-sequencing ageNature Methods, 2014
- Epidermal Growth Factor Receptor Inhibition in Mutation-Positive Non–Small-Cell Lung Cancer: Is Afatinib Better or Simply Newer?Journal of Clinical Oncology, 2013
- Clinical and Organizational Factors in the Initial Evaluation of Patients With Lung CancerChest, 2013
- Predicting the Functional Effect of Amino Acid Substitutions and IndelsPLOS ONE, 2012
- MutationTaster evaluates disease-causing potential of sequence alterationsNature Methods, 2010
- A method and server for predicting damaging missense mutationsNature Methods, 2010
- TP53Mutations and Survival in Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2007